Core Points - *ST San Sheng reached the daily limit of 5.11 yuan, with a rise of 4.96%, and a total market value of 2.104 billion yuan on November 24, 2025 [1] - The company’s restructuring plan has been approved by the court, allowing it to avoid direct bankruptcy liquidation, with a high approval rate from creditors [2] - The introduction of strategic investor Jiheng Group will provide at least 200 million yuan in cash flow support over three years, enhancing the company's core competitiveness in the pharmaceutical sector [2] - The overall performance of the ST sector was active on the same day, contributing to *ST San Sheng's stock price increase, supported by net inflows from major funds [2] - Technical indicators show a bullish trend for the stock, with MACD forming a golden cross and the price breaking through short-term moving average resistance [2]

Core Viewpoint - The company plans to introduce nine investors by utilizing 700 million reserved shares, with the funds aimed at supporting its main business development [1] Group 1 - The introduction of investors will not involve changes in the shareholding of other shareholders [1] - Each of the nine investors has committed to a 24-month lock-up period starting from the date of acquiring the shares [1] - This transaction is classified as a related party transaction and will not result in changes to the company's controlling shareholder or actual controller [1]